top of page

Houston Oncology Summit: Oppenheimer analyst Matthew Biegler talks about synthetic lethality

He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.

Brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page